Prognosis of Acute Kidney Injury:China Collaborative Study on AKI（CCS-AKI）Study

December 10, 2022 updated by: XinLing Liang
Acute kidney injury (AKI) is a common clinical syndrome, especially in the hospital patients. AKI is recognized as an important risk factor for incident chronic kidney disease, accelerated progression to end-stage renal disease,and increased risk of short-term and long-term mortality.This study is to observe the prognosis of hospitalized patients with AKI in China.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

1000000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Guangdong
      • Guangzhou, Guangdong, China
        • Recruiting
        • Guangdong General Hospital
        • Contact:
          • Liang Xinling, MD,PhD
          • Phone Number: 86-13808819770

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Hospitalized patients

Description

Inclusion Criteria:

  • clinically diagnosed with acute kidney injury, according to KDIGO criteria

Exclusion Criteria:

  • Nephrectomy
  • Kidney transplantation
  • Peak serum creatinine of less than 53µ mol/L
  • Serum creatinine decrease after amputation
  • Patients died during hospitalization
  • End-stage kidney disease(chronic kidney disease stage 5)
  • malnutrition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
AKI
non-AKI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All-cause mortality
Time Frame: 5 years
5 years
estimated glomerular filtration rate decline
Time Frame: 2 years
>50% baseline
2 years
Chronic kidney disease classification upgrade
Time Frame: 5 years
5 years
New cardiovascular events
Time Frame: 5 years
5 years

Secondary Outcome Measures

Outcome Measure
Time Frame
AKI recovery
Time Frame: 5 years
5 years
Rehospitalization
Time Frame: 5 years
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

XinLing Liang

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2017

Primary Completion (Anticipated)

December 1, 2027

Study Completion (Anticipated)

December 1, 2027

Study Registration Dates

First Submitted

February 15, 2017

First Submitted That Met QC Criteria

February 19, 2017

First Posted (Actual)

February 23, 2017

Study Record Updates

Last Update Posted (Estimate)

December 13, 2022

Last Update Submitted That Met QC Criteria

December 10, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CCS-AKI P2011-2016

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe